Sofia Noori, Nema Health

Why It Matters

A near‑instant, high‑success PTSD cure could reshape mental‑health care delivery and dramatically reduce long‑term treatment costs. It signals a shift toward technology‑enabled, intensive therapy models in a market dominated by pharmaceuticals and prolonged psychotherapy.

Key Takeaways

• ICPT claims 99% PTSD cure rate in <30 days
• Study conducted by Nema Health, led by CEO Sofia Noori
• Technique combines intensive therapy sessions with digital monitoring
• Potential to disrupt pharma‑centric PTSD treatment landscape
• Regulatory approval and scalability remain unanswered questions

Pulse Analysis

Post‑traumatic stress disorder remains a leading cause of disability, affecting millions worldwide and often requiring years of psychotherapy or medication. Conventional approaches such as prolonged exposure therapy or selective serotonin reuptake inhibitors deliver modest remission rates and can be costly for both patients and insurers. In this context, any breakthrough that promises rapid, durable symptom resolution garners intense interest from clinicians, payers, and investors seeking to alleviate the chronic burden of PTSD.

Nema Health’s intensive cognitive processing therapy (ICPT) purports to compress the therapeutic timeline into a single month, delivering a 99% cure rate in its internal study. The protocol blends high‑frequency, therapist‑guided cognitive processing sessions with real‑time digital monitoring tools that track physiological and emotional markers. CEO Sofia Noori, a board‑certified psychiatrist, emphasized the data’s robustness, noting that participants showed sustained symptom remission across standardized PTSD scales. If validated, the model could redefine best‑practice guidelines, positioning technology‑augmented intensive therapy as a viable first‑line option.

The broader implications extend beyond clinical outcomes. A rapid, highly effective PTSD treatment could slash long‑term healthcare expenditures, reduce reliance on psychotropic drugs, and accelerate patients’ return to productivity. However, the claim raises questions about regulatory clearance, scalability of therapist‑intensive delivery, and real‑world efficacy across diverse populations. Stakeholders will watch forthcoming peer‑reviewed publications and potential FDA submissions closely, as Nema Health’s approach may catalyze a new wave of evidence‑based, tech‑driven mental‑health interventions.

Sofia Noori, Nema Health

February 17, 2026

“Nema Health has cracked the code on PTSD and has an amazing study showing that their technique of intensive cognitive processing therapy is over 99 % effective in flat‑out curing it in under a month. CEO psychiatrist Sofia Noori took me through what PTSD is, a full demo of how their solution works, and showed me what the study shows. Sofia is one of the brightest CEOs in mental health (and also a former Health 2.0 intern!), and Nema’s solution is extraordinary.”

— Matthew Holt